Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Kala Bio Inc (NQ: KALA ) 6.810 +0.050 (+0.74%) Streaming Delayed Price Updated: 10:31 AM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Kala Bio Inc < Previous 1 2 Next > KALA BIO Announces $12,500,000 Private Placement June 27, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO to Present at Jefferies Global Healthcare Conference May 29, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update May 14, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update March 29, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference February 26, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference February 06, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 19, 2024 From KALA BIO, Inc. Via GlobeNewswire KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update November 13, 2023 From KALA BIO, Inc. Via GlobeNewswire KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) September 20, 2023 From KALA BIO, Inc. Via GlobeNewswire KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference September 05, 2023 From KALA BIO, Inc. Via GlobeNewswire KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update August 04, 2023 From KALA BIO, Inc. Via GlobeNewswire KALA BIO to Participate in Upcoming Investor Conferences in August August 02, 2023 From KALA BIO, Inc. Via GlobeNewswire Kala Pharmaceuticals Announces Name Change to KALA BIO August 02, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) July 19, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 23, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals to Present at the Jefferies Healthcare Conference June 02, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update May 09, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Combangio, Inc., a Wholly Owned Subsidiary of Kala Pharmaceuticals, Awarded $15 Million by California Institute for Regenerative Medicine to Support Ongoing KPI-012 Program for the Treatment of PCED April 28, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect April 12, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Appoints Dr. Francis Mah as Chief Medical Advisor March 29, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Announces Positive Safety Update from Cohort 1 of CHASE Phase 2b Clinical Trial Evaluating KPI-012 in Patients with PCED March 27, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference March 08, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update March 03, 2023 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Here’s Why Sotera Health Company Stock Just Doubled in a Day January 11, 2023 Sotera Health Company (NASDAQ: SHC) is a leading global provider of mission-critical sterilization solutions, lab testing, and advisory services. Via MarketBeat Topics Emissions Initial Public Offering Exposures Securities Market Kala Pharmaceuticals Up 400% In The Past Month, What's Next ? January 10, 2023 Kala pharmaceuticals underwent a massive rally over the past few days, and by all indications, the stock price is now headed toward a bottom. Via MarketBeat Exposures Product Safety Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030 December 30, 2022 EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END Via FinancialNewsMedia Kala Pharmaceuticals (NASDAQ: KALA) Says FDA Accepted its IND Application for KPI-012 and Treatment of PCED December 28, 2022 Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research, development and Via Spotlight Growth Exposures Product Safety Kala Pharmaceuticals Announces FDA Acceptance of IND Application for KPI-012 for the Treatment of PCED December 27, 2022 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Announces Submission of Investigational New Drug Application for KPI-012 for the Treatment of Persistent Corneal Epithelial Defect November 28, 2022 From Kala Pharmaceuticals, Inc. Via GlobeNewswire Kala Pharmaceuticals Announces Up to $31 Million Private Placement Financing November 28, 2022 From Kala Pharmaceuticals, Inc. Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.